GlassScriptPhysician profile
Eric T Rome
NPI 1982883476
$1,423.82
in general payments reported to CMS, 2019-2025
23 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $208 · 2021: $339 · 2022: $180 · 2023: $273 · 2024: $28.25 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $364.03 | 2019-2025 | Cardiomems, Amplatzer Amulet, Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $124.92 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $116.35 | 2020-2023 | |
| Amgen INC. | $114.19 | 2019-2021 | |
| Amarin Pharma, INC. | $91.99 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $71.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $54.16 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $50.30 | 2021-2023 | Eliquis |
| Chiesi USA, INC. | $49.10 | 2020 | |
| Impulse Dynamics (USA) INC. | $37.88 | 2023 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.09 | 2019-2023 | Lifevest |
| Heartflow, INC. | $35.75 | 2025 | |
| Merck Sharp & Dohme LLC | $29.77 | 2021-2023 | Verquvo |
| Lantheus Medical Imaging, INC. | $29.64 | 2023 | Definity |
| Kiniksa Pharmaceuticals International, Plc | $28.25 | 2024 | Arcalyst |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $27.92 | 2019-2021 | |
| Medtronic Vascular, INC. | $27.55 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $25.76 | 2021-2025 | Farxiga |
| Bridgebio Pharma, INC. | $25.18 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $24.71 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $22.17 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $19.92 | 2023 | Inpefa |
| Gilead Sciences, INC. | $16.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Rome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.